Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results from a study by the SWOG Cancer Research Network were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA6). The study—S1801—was led by Sapna Patel, MD, Chair of the SWOG Melanoma Committee and Associate Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.
It's not just what you give, it's when you give it. The S1801 study demonstrates the same treatment for resectable melanoma given before surgery can generate better outcomes.— Sapna Patel, MD
Tweet this quote
“It's not just what you give, it's when you give it. The S1801 study demonstrates the same treatment for resectable melanoma given before surgery can generate better outcomes,” Dr. Patel said. “In this case, we used the immune checkpoint inhibitor pembrolizumab. This treatment relies on the presence of preexisting T cells coming in contact with cancer cells in the body to generate an immune response, and we found that starting treatment before the melanoma is removed—and with it, the bulk of tumor-specific T cells—leads to a greater response than giving it after surgery.”
The mechanism of action of immune checkpoint inhibitors such as pembrolizumab is often described as “taking the brakes off” the immune system’s response to tumor cells. The S1801 researchers hypothesized that there would be a larger antitumor immune response and longer immunologic memory if pembrolizumab was administered while the melanoma tumor was still in the body as opposed to after that tumor had been removed, when the immune system would be responding primarily to micrometastatic cancer cells.
Study Details
To test this hypothesis, S1801 investigators enrolled 345 participants with stage IIIB through stage IV melanoma that was deemed operable. Participants aged 18 to 90 years were randomly assigned to receive either upfront surgery followed by 200 mg of pembrolizumab every 3 weeks (adjuvant therapy) for a total of 18 doses, or to 200 mg of pembrolizumab every 3 weeks for three doses leading up to surgery (neoadjuvant therapy), then an additional 15 doses following surgery.
The primary endpoint measured was the duration of event-free survival, defined as the time from random assignment to the occurrence of one of the following: disease progression or toxicity that resulted in not receiving surgery, failure to begin adjuvant therapy within 84 days of surgery, melanoma recurrence after surgery, or death from any cause.
Results
With a median follow-up of 14.7 months, event-free survival was significantly longer in the neoadjuvant therapy arm, with a hazard ratio of 0.58 when compared to the adjuvant therapy arm, which corresponds to a 42% lower event rate in the patients receiving the neoadjuvant regimen.
“Our study noted a significant improvement in event-free survival in the neoadjuvant regimen compared to the adjuvant regimen,” Dr. Patel said. “Importantly, a similar number of patients in both arms experienced events before initiating adjuvant pembrolizumab, but the rate of events after initiating adjuvant therapy was higher in the adjuvant arm.”
The researchers found that the benefit from neoadjuvant therapy was consistent across a range of factors including patient age, sex, performance status, and stage of disease. They also found that the rates of adverse events were similar across both arms of the study and that neoadjuvant pembrolizumab did not result in an increase in adverse events related to surgery.
“Based on the findings from S1801, patients with high-risk melanoma should start immunotherapy prior to surgery to generate an immune response while the bulk of the melanoma and the antitumor T cells are intact,” Dr. Patel said. “Future studies can explore de-escalation strategies for both surgery and adjuvant therapy, as well as approaches for patients whose melanoma does not respond to neoadjuvant therapy.”
Disclosure: S1801 is supported by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), led by SWOG, and conducted by the NIH-funded National Clinical Trials Network (NCTN). S1801 is funded by the NIH/NCI through grants CA180888, CA180819, CA180821, and CA180868 and in part by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, New Jersey, through a Cooperative Research and Development Agreement with the NCI. The study was also supported by NIH/NCI grant UG1CA233329. For full disclosures of the study authors, visit oncologypro.esmo.org.
